Supplements for Cholesterol
Red yeast rice (Monascus purpureus)
1200-2400 mg, once per day, minimum 8 to 12 weeks (10)
- Patients with dyslipidemia who were unable to continue statin use due to myalgia experienced decreased low-density lipoprotein (LDL) cholesterol by 43 mg/dL (1.11 mmol/L) at 12 weeks, and 0.90 mmol/L at 24 weeks, when taking 1800 mg twice daily, compared to baseline and placebo (1)
- A meta-analysis showed weighted mean difference in total cholesterol levels decreased by 0.91 mmol/L, triglycerides by 0.41 mmol/L, and LDL cholesterol by 0.73 mmol/L as well as increased high-density lipoprotein (HDL) by 0.15 mmol/L (10)
- Monocolin K-rich red yeast rice was found to be more effective in lowering total cholesterol and LDL cholesterol when compared to GABA-rich red yeast rice in patients with hyperlipidemia (24)
- A meta-analysis showed that in a number of small trials, red yeast rice was found to have similar effects to statins in ability to improve cholesterol profile (12)
200 mg, once per day, minimum 3 months (23)
- Systematic review and meta-analysis of seven trials found supplementation effective in reducing triglyceride levels observed with consistent supplementation (20)
- Meta-analysis of eight trials found total cholesterol decrease of 1.07 (standardized mean difference) and HDL increased by 1.30 (standardized mean difference) in patients with coronary artery disease (6)
- Patients with dyslipidemia supplemented with 120 mg of CoQ10 for 24 weeks experienced a decrease in blood pressure, serum triglyceride, and LDL cholesterol; as well as an increase in total antioxidant diastolic blood pressure, and ApoA-I, demonstrating in an overall decrease in cardiovascular disease risk factors, when 120 mg per day (26)
- After supplementing with 200 mg for 1 week, an increase in serum CoQ10 correlated with improved HDL cholesterol as well as inhibition of monocyte-derived macrophage foam cell formation, suggesting overall improvement in cardiovascular health (25)
Products:
Omega-3 fatty acids
2-4 g, total per day, minimum 3 months (Dose varies greatly based on EPA/DHA content) (23)(5)(9)
- By reducing VLDL, both EPA, and DHA when administered independently resulted in reduced fasting circulating triglyceride levels (13)
- Systematic review of six studies found supplementation of EPA or DHA greater than 2 g per day (with greater than or equal to 90% purity) was found to have a triglyceride concentration lowering effect, with DHA having a more significant impact at decreasing triglyceride concentration (5)
- Systematic review and meta-analysis found when given omega-3 fatty acids during statin therapy, an improvement in decreasing total cholesterol was demonstrated (2)
- Fasting serum triglyceride decreased by 25.9%, 25.5%, and 30.9% in groups supplemented with 2, 3, and 4 grams of omega-3 fatty acids respectively in patients with severe hypertriglyceridemia (8)
- When given in addition to rosuvastatin, 4 g per day of omega 3 fatty acids decreased triglyceride levels by 26.3% (11.4% in placebo) and non-HDL-C by 10.7% (2.2% in placebo), with combined supplementation showing the greatest impact in patients with residual hypertriglyceridemia (9)
Products:
Garlic (Allium sativum)
400-600 mg, once per day, minimum 12 weeks (22)(19)
- Increase in HDL (high-density lipoprotein) in addition to a decrease in alipoprotein B and an increase in the LDL/alipoprotein B ratio was observed after supplementation with 6 g/day aged black garlic for 12 weeks (7)
- Supplementation decreased total cholesterol by 11.5%, decreased LDL by 13.8% and increased HDL cholesterol by 11.5% in men aged 35-70 with mild hypocholesterolemiam when given 600 mg per day (19)
- Meta-analysis of 14 papers found hyperlipidemia improved as demonstrated by n improvement in total cholesterol (21)
- Inflammation decreased as demonstrated by a decrease in arterial stiffness index, high-sensitivity C-reactive protein, LDL cholesterol, and total antioxidant status in obese patients compared to placebo, when given 400 mg per day (22)
- A meta-analysis showed that, when use of garlic supplementation was continued for at least 2 months, a decrease in total serum cholesterol by 8% and decreased risk of coronary event by 38% was observed in people 50 years of age (17)
- Garlic supplementation in patients with hypertension decreased blood pressure, helped to decrease slightly elevated cholesterol and increase immune function as shown by a decrease in blood pressure, and improvement in blood lipids when treated for a minimum of 2 weeks (16)
L-Carnitine
2 g per day, minimum of 12 weeks (4)(11)
- Patients with hyperlipidemia demonstrated a decrease in lipoprotein (a) by 19.4% compared to 6.7% in placebo group when supplemented with 2 g per day of L-carnitine for 12 weeks; similar decreases in total cholesterol, LDL, apolipoprotein (b), and triacylglycerols (4)
- Decreased oxidation of LDL cholesterol occurred as demonstrated by a decrease in oxidized LDL levels by 15.1 U/L compared to 3.0 U/L in placebo, and LDL cholesterol by 0.45 mmol/L compared to 0.16 mmol/L in placebo in patients with type 2 diabetes when given 2 g per day (11)
- Decreases in plasma lipoprotein (a) were observed in hypercholesterolemic patients newly diagnosed with type 2 diabetes when supplemented with 1g twice per day of L-carnitine compared to placebo (3)
- 77.8% of patients with elevated Lp(a) experienced a reduction in lipoprotein (a) when supplemented compared to 38.9% in placebo; patients with a higher elevation at baseline experienced more significant decreases in Lp(a) with 2 g per day supplementation (18)
Products:
References
- Becker, D. J., Gordon, R. Y., Halbert, S. C., French, B., Morris, P. B., & Rader, D. J. (2009). Red yeast rice for dyslipidemia in statin-intolerant patients: a randomized trial. Annals of Internal Medicine, 150(12), 830–839, W147–W149. https://pubmed.ncbi.nlm.nih.gov/19528562/ (C)
- Choi, H. D., & Chae, S. M. (2018). Comparison of efficacy and safety of combination therapy with statins and omega-3 fatty acids versus statin monotherapy in patients with dyslipidemia: A systematic review and meta-analysis. Medicine, 97(50), e13593. https://pubmed.ncbi.nlm.nih.gov/30558030/ (A)
- Derosa, G., Cicero, A. F. G., Gaddi, A., Mugellini, A., Ciccarelli, L., & Fogari, R. (2003). The effect of L-carnitine on plasma lipoprotein(a) levels in hypercholesterolemic patients with type 2 diabetes mellitus. Clinical Therapeutics, 25(5), 1429–1439. https://pubmed.ncbi.nlm.nih.gov/12867219/ (B)
- Florentin, M., Elisaf, M. S., Rizos, C. V., Nikolaou, V., Bilianou, E., Pitsavos, C., & Liberopoulos, E. N. (2017). L-Carnitine/Simvastatin Reduces Lipoprotein (a) Levels Compared with Simvastatin Monotherapy: A Randomized Double-Blind Placebo-Controlled Study. Lipids, 52(1), 1–9. https://pubmed.ncbi.nlm.nih.gov/27914033/ (B)
- Innes, J. K., & Calder, P. C. (2018). The Differential Effects of Eicosapentaenoic Acid and Docosahexaenoic Acid on Cardiometabolic Risk Factors: A Systematic Review. International Journal of Molecular Sciences, 19(2). https://doi.org/10.3390/ijms19020532 https://pubmed.ncbi.nlm.nih.gov/29425187/ (A)
- Jorat, M. V., Tabrizi, R., Mirhosseini, N., Lankarani, K. B., Akbari, M., Heydari, S. T., Mottaghi, R., & Asemi, Z. (2018). The effects of coenzyme Q10 supplementation on lipid profiles among patients with coronary artery disease: a systematic review and meta-analysis of randomized controlled trials. Lipids in Health and Disease, 17(1), 230. https://pubmed.ncbi.nlm.nih.gov/30296936/ (A)
- Jung, E.-S., Park, S.-H., Choi, E.-K., Ryu, B.-H., Park, B.-H., Kim, D.-S., Kim, Y.-G., & Chae, S.-W. (2014). Reduction of blood lipid parameters by a 12-wk supplementation of aged black garlic: a randomized controlled trial. Nutrition , 30(9), 1034–1039. https://pubmed.ncbi.nlm.nih.gov/24976429/ (C)
- Kastelein, J. J. P., Maki, K. C., Susekov, A., Ezhov, M., Nordestgaard, B. G., Machielse, B. N., Kling, D., & Davidson, M. H. (2014). Omega-3 free fatty acids for the treatment of severe hypertriglyceridemia: the EpanoVa fOr Lowering Very high triglyceridEs (EVOLVE) trial. Journal of Clinical Lipidology, 8(1), 94–106. https://pubmed.ncbi.nlm.nih.gov/24528690/ (C)
- Kim, C. H., Han, K. A., Yu, J., Lee, S. H., Jeon, H. K., Kim, S. H., Kim, S. Y., Han, K. H., Won, K., Kim, D.-B., Lee, K.-J., Min, K., Byun, D. W., Lim, S.-W., Ahn, C. W., Kim, S., Hong, Y. J., Sung, J., Hur, S.-H., … Kim, H.-S. (2018). Efficacy and Safety of Adding Omega-3 Fatty Acids in Statin-treated Patients with Residual Hypertriglyceridemia: ROMANTIC (Rosuvastatin-OMAcor iN residual hyperTrIglyCeridemia), a Randomized, Double-blind, and Placebo-controlled Trial. Clinical Therapeutics, 40(1), 83–94. https://pubmed.ncbi.nlm.nih.gov/29223557/ (B)
- Liu, J., Zhang, J., Shi, Y., Grimsgaard, S., Alraek, T., & Fønnebø, V. (2006). Chinese red yeast rice (Monascus purpureus) for primary hyperlipidemia: a meta-analysis of randomized controlled trials. Chinese Medicine, 1, 4. https://pubmed.ncbi.nlm.nih.gov/17302963/ (A)
- Malaguarnera, M., Vacante, M., Avitabile, T., Malaguarnera, M., Cammalleri, L., & Motta, M. (2009). L-Carnitine supplementation reduces oxidized LDL cholesterol in patients with diabetes. The American Journal of Clinical Nutrition, 89(1), 71–76. https://pubmed.ncbi.nlm.nih.gov/19056606/ (C)
- Ong, Y. C., & Aziz, Z. (2016). Systematic review of red yeast rice compared with simvastatin in dyslipidaemia. Journal of Clinical Pharmacy and Therapeutics, 41(2), 170–179. https://pubmed.ncbi.nlm.nih.gov/26956355/ (A)
- Oscarsson, J., & Hurt-Camejo, E. (2017). Omega-3 fatty acids eicosapentaenoic acid and docosahexaenoic acid and their mechanisms of action on apolipoprotein B-containing lipoproteins in humans: a review. Lipids in Health and Disease, 16(1), 149. https://pubmed.ncbi.nlm.nih.gov/28797250/ (A)
- Products – Data Briefs – Number 290 – October 2017. (2019, June 6). https://www.cdc.gov/nchs/products/databriefs/db290.htm https://www.cdc.gov/nchs/products/databriefs/db290.htm (F)
- Prospective Studies Collaboration, Lewington, S., Whitlock, G., Clarke, R., Sherliker, P., Emberson, J., Halsey, J., Qizilbash, N., Peto, R., & Collins, R. (2007). Blood cholesterol and vascular mortality by age, sex, and blood pressure: a meta-analysis of individual data from 61 prospective studies with 55,000 vascular deaths. The Lancet, 370(9602), 1829–1839. https://pubmed.ncbi.nlm.nih.gov/18061058/ (A)
- Ried, K. (2016). Garlic Lowers Blood Pressure in Hypertensive Individuals, Regulates Serum Cholesterol, and Stimulates Immunity: An Updated Meta-analysis and Review. The Journal of Nutrition, 146(2), 389S – 396S. https://pubmed.ncbi.nlm.nih.gov/26764326/ (A)
- Ried, K., Toben, C., & Fakler, P. (2013). Effect of garlic on serum lipids: an updated meta-analysis. Nutrition Reviews, 71(5), 282–299. https://pubmed.ncbi.nlm.nih.gov/23590705/ (A)
- Sirtori, C. R., Calabresi, L., Ferrara, S., Pazzucconi, F., Bondioli, A., Baldassarre, D., Birreci, A., & Koverech, A. (2000). L-carnitine reduces plasma lipoprotein(a) levels in patients with hyper Lp(a). Nutrition, Metabolism, and Cardiovascular Diseases: NMCD, 10(5), 247–251. https://pubmed.ncbi.nlm.nih.gov/11213533/ (C)
- Sobenin, I. A., Andrianova, I. V., Demidova, O. N., Gorchakova, T., & Orekhov, A. N. (2008). Lipid-lowering effects of time-released garlic powder tablets in double-blinded placebo-controlled randomized study. Journal of Atherosclerosis and Thrombosis, 15(6), 334–338. https://pubmed.ncbi.nlm.nih.gov/19060427/ (C)
- Suksomboon, N., Poolsup, N., & Juanak, N. (2015). Effects of coenzyme Q10 supplementation on metabolic profile in diabetes: a systematic review and meta-analysis. Journal of Clinical Pharmacy and Therapeutics, 40(4), 413–418. https://pubmed.ncbi.nlm.nih.gov/25913756/ (A)
- Sun, Y.-E., Wang, W., & Qin, J. (2018). Anti-hyperlipidemia of garlic by reducing the level of total cholesterol and low-density lipoprotein: A meta-analysis. Medicine, 97(18), e0255. https://pubmed.ncbi.nlm.nih.gov/29718835/ (A)
- Szulińska, M., Kręgielska-Narożna, M., Świątek, J., Styś, P., Kuźnar-Kamińska, B., Jakubowski, H., Walkowiak, J., & Bogdański, P. (2018). Garlic extract favorably modifies markers of endothelial function in obese patients -randomized double blind placebo-controlled nutritional intervention. Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie, 102, 792–797. https://pubmed.ncbi.nlm.nih.gov/29604599/ (B)
- Tóth, Š., Šajty, M., Pekárová, T., Mughees, A., Štefanič, P., Katz, M., Spišáková, K., Pella, J., & Pella, D. (2017). Addition of omega-3 fatty acid and coenzyme Q10 to statin therapy in patients with combined dyslipidemia. Journal of Basic and Clinical Physiology and Pharmacology, 28(4), 327–336. https://pubmed.ncbi.nlm.nih.gov/28541926/ (C)
- Wang, T.-J., Lien, A. S.-Y., Chen, J.-L., Lin, C.-H., Yang, Y.-S., & Yang, S.-H. (2019). A Randomized Clinical Efficacy Trial of Red Yeast Rice (Monascus pilosus) Against Hyperlipidemia. The American Journal of Chinese Medicine, 47(2), 323–335. https://pubmed.ncbi.nlm.nih.gov/30871361/ (B)
- Yan, X., Shen, T., Jiang, X., Tang, X., Wang, D., Li, H., & Ling, W. (2015). Coenzyme Q10 consumption promotes ABCG1-mediated macrophage cholesterol efflux: a randomized, double-blind, placebo-controlled, cross-over study in healthy volunteers. Molecular Nutrition & Food Research, 59(9), 1725–1734. https://pubmed.ncbi.nlm.nih.gov/26081100/ (C)
- Zhang, P., Yang, C., Guo, H., Wang, J., Lin, S., Li, H., Yang, Y., & Ling, W. (2018). Treatment of coenzyme Q10 for 24 weeks improves lipid and glycemic profile in dyslipidemic individuals. Journal of Clinical Lipidology, 12(2), 417–427.e5. https://pubmed.ncbi.nlm.nih.gov/29454678/ (B)